Quantum Genesis AI Corp. (OTC: QGAI) issued a press release on May 19, 2026, to clarify the relationship between its research activities and those of Quantumzyme LLP, a separate entity based in Bengaluru, India. The company emphasized that Quantumzyme LLP is not a subsidiary or affiliate, but noted that certain prior press releases referenced scientific publications that identified Quantumzyme LLP and the affiliations of contributing researchers at the time of submission.
The clarification addresses disclosures made in press releases dated November 5, 2025, and February 12, 2026, which cited research in the broader enzyme engineering and biocatalysis field. Quantum Genesis AI stated that its Chief Executive Officer, Naveen Kulkarni, had transferred intellectual property, know-how, and related rights to the company under an Asset Purchase Agreement dated February 21, 2023, and a subsequent confirmatory assignment disclosed in a Form 8-K filed on April 29, 2026. The company believes that this transfer includes technology and methodologies developed by Mr. Kulkarni, whether directly or through Quantumzyme LLP, that pertain to its core business.
The statement is significant as it delineates the scope of the company's intellectual property assets amid potential investor and partner confusion. By distinguishing Quantumzyme LLP from Quantum Genesis AI, the company aims to clarify ownership of key technologies in enzyme engineering, molecular modeling, and biocatalysis—areas central to its operations. The company asserts that research activities based on the transferred technology platform fall under its rights, reinforcing its control over critical IP.
This announcement underscores the importance of corporate governance and transparency in biotechnology ventures, especially those involving complex IP arrangements. For investors, the clarification provides assurance about the company's asset base and reduces ambiguity regarding the origin of its research. The company's focus on leveraging artificial intelligence and computational modeling for scientific innovation remains a key differentiator, and this clarification helps solidify its position in the field.
For further details, the company directs readers to its website at qgaicorp.com and its profile on OTC Markets.
